(HRTX) Heron Therapeuti - Ratings and Ratios
Sustol, Cinvanti, Zynrelef, Aponvie, Biochronomer
HRTX EPS (Earnings per Share)
HRTX Revenue
Description: HRTX Heron Therapeuti
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a commercial-stage biotechnology company that focuses on developing and commercializing therapeutics that enhance medical care. The companys proprietary Biochronomer technology enables the delivery of therapeutic levels of short-acting pharmacological agents over a prolonged period, improving patient outcomes.
The companys product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for preventing nausea and vomiting associated with cancer chemotherapy. Heron Therapeutics is also developing ZYNRELEF, a dual-acting local anesthetic, and APONVIE, an intravenous formulation for preventing postoperative nausea and vomiting.
From a financial perspective, Heron Therapeutics has a market capitalization of $315.81 million and a Return on Equity (ROE) of 22.24%, indicating a relatively strong financial performance. Key Performance Indicators (KPIs) to monitor include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of revenue. Additionally, the companys cash burn rate and cash reserves are essential metrics to track, given the high R&D expenses associated with the biotechnology industry.
To further evaluate Heron Therapeutics potential, its essential to analyze its competitive landscape, including its market share and positioning relative to peers. The companys pipeline and development programs, including ZYNRELEF and APONVIE, are also crucial in determining its future growth prospects. Furthermore, monitoring the companys regulatory updates, clinical trial results, and commercialization progress will be vital in assessing its potential for long-term success.
HRTX Stock Overview
| Market Cap in USD | 204m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1987-08-26 |
HRTX Stock Ratings
| Growth Rating | -58.0% |
| Fundamental | 44.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -46.3% |
| Analyst Rating | 4.67 of 5 |
HRTX Dividends
Currently no dividends paidHRTX Growth Ratios
| Growth Correlation 3m | -91.7% |
| Growth Correlation 12m | 7.5% |
| Growth Correlation 5y | -82.2% |
| CAGR 5y | -34.88% |
| CAGR/Max DD 3y | -0.39 |
| CAGR/Mean DD 3y | -0.61 |
| Sharpe Ratio 12m | -1.57 |
| Alpha | 0.17 |
| Beta | 0.590 |
| Volatility | 82.35% |
| Current Volume | 1360.9k |
| Average Volume 20d | 1317.2k |
| Stop Loss | 1.1 (-9.1%) |
| Signal | -1.05 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-931.0k TTM) > 0 and > 6% of Revenue (6% = 8.98m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA 17.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -31.85% (prev 81.29%; Δ -113.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.12 (>3.0%) and CFO -28.1m <= Net Income -931.0k (YES >=105%, WARN >=100%) |
| Net Debt (160.2m) to EBITDA (6.92m) ratio: 23.14 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (154.0m) change vs 12m ago 1.13% (target <= -2.0% for YES) |
| Gross Margin 74.61% (prev 65.49%; Δ 9.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.50% (prev 62.51%; Δ 3.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.78 (EBITDA TTM 6.92m / Interest Expense TTM 5.93m) >= 6 (WARN >= 3) |
Altman Z'' -35.93
| (A) -0.21 = (Total Current Assets 210.9m - Total Current Liabilities 258.6m) / Total Assets 232.1m |
| (B) -8.27 = Retained Earnings (Balance) -1.92b / Total Assets 232.1m |
| warn (B) unusual magnitude: -8.27 — check mapping/units |
| (C) 0.02 = EBIT TTM 4.60m / Avg Total Assets 225.1m |
| (D) -7.39 = Book Value of Equity -1.92b / Total Liabilities 259.3m |
| Total Rating: -35.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 44.56
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -7.11% = -3.56 |
| 3. FCF Margin -16.19% = -6.07 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 25.63 = -2.50 |
| 6. ROIC - WACC (= -1.93)% = -2.41 |
| 7. RoE data missing |
| 8. Rev. Trend 90.58% = 6.79 |
| 9. EPS Trend 86.13% = 4.31 |
What is the price of HRTX shares?
Over the past week, the price has changed by -4.72%, over one month by -6.92%, over three months by -37.95% and over the past year by -36.32%.
Is Heron Therapeuti a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRTX is around 0.86 USD . This means that HRTX is currently overvalued and has a potential downside of -28.93%.
Is HRTX a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.8 | 292.6% |
| Analysts Target Price | 4.8 | 292.6% |
| ValueRay Target Price | 0.9 | -23.1% |
Last update: 2025-09-06 04:39
HRTX Fundamental Data Overview
CCE Cash And Equivalents = 40.6m USD (Cash And Short Term Investments, last quarter)
P/S = 1.362
P/B = 12.6037
P/EG = -0.18
Beta = 1.229
Revenue TTM = 149.7m USD
EBIT TTM = 4.60m USD
EBITDA TTM = 6.92m USD
Long Term Debt = 747.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 176.7m USD (from shortTermDebt, last quarter)
Debt = 177.5m USD (Calculated: Short Term 176.7m + Long Term 747.0k)
Net Debt = 160.2m USD (from netDebt column, last quarter)
Enterprise Value = 340.7m USD (203.9m + Debt 177.5m - CCE 40.6m)
Interest Coverage Ratio = 0.78 (Ebit TTM 4.60m / Interest Expense TTM 5.93m)
FCF Yield = -7.11% (FCF TTM -24.2m / Enterprise Value 340.7m)
FCF Margin = -16.19% (FCF TTM -24.2m / Revenue TTM 149.7m)
Net Margin = -0.62% (Net Income TTM -931.0k / Revenue TTM 149.7m)
Gross Margin = 74.61% ((Revenue TTM 149.7m - Cost of Revenue TTM 38.0m) / Revenue TTM)
Tobins Q-Ratio = -0.18 (set to none) (Enterprise Value 340.7m / Book Value Of Equity -1.92b)
Interest Expense / Debt = 0.28% (Interest Expense 500.0k / Debt 177.5m)
Taxrate = 21.0% (US default)
NOPAT = 3.63m (EBIT 4.60m * (1 - 21.00%))
Current Ratio = 0.82 (Total Current Assets 210.9m / Total Current Liabilities 258.6m)
Debt / EBITDA = 25.63 (Net Debt 160.2m / EBITDA 6.92m)
Debt / FCF = -7.32 (Debt 177.5m / FCF TTM -24.2m)
Total Stockholder Equity = -32.3m (last 4 quarters mean)
RoA = -0.40% (Net Income -931.0k, Total Assets 232.1m )
RoE = unknown (Net Income TTM -931.0k / Total Stockholder Equity -32.3m)
RoCE = unknown (Ebit 4.60m / (Equity -32.3m + L.T.Debt 747.0k))
RoIC = 2.55% (NOPAT 3.63m / Invested Capital 142.5m)
WACC = 4.48% (E(203.9m)/V(381.4m) * Re(8.19%)) + (D(177.5m)/V(381.4m) * Rd(0.28%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.96%
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -24.2m)
EPS Correlation: 86.13 | EPS CAGR: 333.3% | SUE: -0.13 | # QB: 0
Revenue Correlation: 90.58 | Revenue CAGR: 13.04% | SUE: N/A | # QB: None
Additional Sources for HRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle